Z-338
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dyspepsia
Conditions
Dyspepsia
Trial Timeline
Mar 1, 2014 → Apr 1, 2017
NCT ID
NCT01973790About Z-338
Z-338 is a phase 3 stage product being developed by Zeria Pharmaceutical for Dyspepsia. The current trial status is completed. This product is registered under clinical trial identifier NCT01973790. Target conditions include Dyspepsia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01973790 | Phase 3 | Completed |
| NCT00458328 | Phase 2 | Completed |
| NCT00333372 | Phase 2 | Completed |
| NCT00323817 | Phase 2 | Completed |
| NCT00298194 | Phase 2 | Completed |
Competing Products
20 competing products in Dyspepsia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YH12852 0.1 mg + YH12852 0.25 mg + YH12852 0.5 mg + Placebo | Yuhan | Phase 2 | 52 |
| YM443 + Placebo + Moxifloxacin | Astellas Pharma | Phase 1 | 33 |
| YM443 | Astellas Pharma | Phase 3 | 77 |
| Cinitapride + domperidone | Eisai | Phase 3 | 77 |
| Rabeprazole + Rabeprazole + Rabeprazole + Placebo | Eisai | Phase 2 | 52 |
| Imonogas + Espumisan | Johnson & Johnson | Phase 3 | 77 |
| esomeprazole | AstraZeneca | Approved | 85 |
| Esomeprazole Magnesium | AstraZeneca | Approved | 85 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Tegaserod and Placebo | Novartis | Approved | 85 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Z-338 | Zeria Pharmaceutical | Phase 2 | 51 |
| Z-338 | Zeria Pharmaceutical | Phase 2 | 51 |
| Z-338 | Zeria Pharmaceutical | Phase 2 | 51 |
| Z-338 + Placebo | Zeria Pharmaceutical | Phase 3 | 76 |
| Acotiamide hydrochloride hydrate + Placebo | Zeria Pharmaceutical | Phase 3 | 76 |